TradeOrgs
  • 🇮🇳 India
  • 🇺🇸 US
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← US stocks

🇺🇸AAPG

Ascentage Pharma Group International - American Depository Shares

NASDAQ
$13.01
▼ $2.36 (-15.3%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 18 Nov 2026
H $22.58L $13.11-37.9%
$22.58$20.69$18.79$16.9$15.01$13.11$13.14
RSI (14)

Technical signal

Strong sell-50
RSI (14)35
oversold 30overbought 70
Trend
Downtrend
MACD
Bearish
Bollinger
Below lower band
vs 20-day
below
vs 50-day
below
vs 200-day
below
Support
$13.11
Resistance
$16.55
  • Price is below its 50-day average (medium-term weakness).
  • Price is below the lower Bollinger Band (stretched to the downside).

Signal backtest · 2026-02-18 → 2026-11-17

Strategy return
-38.3%
Buy & hold
-46.8%
Trades
6
Win rate
0%

$100,000.00 invested would be worth $61,661.07 (-38.3%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About Ascentage Pharma Group Internat· Biotechnology

source: yahoo

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has strategic partnership with biotechnology and pharmaceutical companies; research institutions; and Peking University to build a collaborative system for hematological oncology. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.

Sector
Healthcare
Industry
Biotechnology
Employees
828
Headquarters
Suzhou, China
www.ascentage.cn ↗

Fundamentals

No fundamental data is currently available for this listing from our data providers.

Recent news

News sentiment:— Neutral1↑ · 1↓ · 6–
  • Ascentage Pharma's Lisaftoclax Included in China's 2026 National Reimbursement Drug List— Neutral
    MT Newswires · 16 Nov 2026
  • Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib— Neutral
    GlobeNewswire · 15 Nov 2026
  • Ascentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026— Neutral
    GlobeNewswire · 04 Nov 2026

Educational technical indicators — not investment advice. TradeOrgs does not place trades.

Ascentage Pharma to Participate in Two Upcoming Investor Conferences in London— Neutral
GlobeNewswire · 03 Nov 2026
  • William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage▲ Positive
    Business Wire · 21 Oct 2026
  • Ascentage Pharma's Lisaftoclax Granted China Breakthrough Designation— Neutral
    MT Newswires · 21 Oct 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.